Daniel M. Junius
Daniel M. Junius's purchase track record
Daniel M. Junius has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/10/2023 | CBIO | $47K | -9.7% | -23.9% | +5.9% |
| 11/17/2022 | CBIO | $37K | -4.5% | +2.8% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
Transaction History
| IDXX | ▲ Buy | Option Exercise | 257 | $0 | 5/7/2026 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 1,404 | $345K | 5/13/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 1,279 | $363K | 5/13/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 2,683 | $1.4M | 5/13/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 262 | $0 | 5/6/2025 | View on chart |
| CBIO | ▲ Buy | Grant | 5,209 | $16K | 3/29/2024 | View on chart |
| IDXX | ▲ Buy | Grant | 14 | $7K | 1/30/2024 | View on chart |
| IDXX | ▲ Buy | Grant | 19 | $8K | 10/30/2023 | View on chart |
| IDXX | ▲ Buy | Grant | 14 | $8K | 7/28/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 30,000 | $47K | 5/10/2023 | View on chart |
| IDXX | ▲ Buy | Grant | 13 | $6K | 4/28/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 2,187 | $452K | 2/16/2023 | View on chart |
| IDXX | ▼ Sell | Open Market | 2,187 | $1.1M | 2/16/2023 | View on chart |
| IDXX | ▲ Buy | Grant | 14 | $7K | 1/30/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 3,046 | $488K | 12/5/2022 | View on chart |
| IDXX | ▼ Sell | Open Market | 3,046 | $1.3M | 12/5/2022 | View on chart |
| CBIO | ▲ Buy | Open Market | 20,000 | $37K | 11/17/2022 | View on chart |
| IDXX | ▲ Buy | Grant | 18 | $7K | 10/28/2022 | View on chart |
| IDXX | ▲ Buy | Grant | 16 | $6K | 7/29/2022 | View on chart |
| IDXX | ▲ Buy | Grant | 15 | $6K | 4/29/2022 | View on chart |
| IDXX | ▲ Buy | Grant | 13 | $6K | 1/28/2022 | View on chart |
| IDXX | ▲ Buy | Grant | 10 | $7K | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
KeyBanc initiates IDEXX coverage with Sector Weight rating
KeyBanc has started covering IDEXX Laboratories, assigning it a Sector Weight rating. This move adds to analyst attention as investors look ahead to the company's upcoming Q3 2026 earnings report. The stock is currently trading near its 52-week high, reflecting strong recent performance.
KeyBanc initiates IDEXX coverage with Sector Weight rating. KeyBanc has started covering IDEXX Laboratories, assigning it a Sector Weight rating. This move adds to analyst attention as investors look ahead to the company's upcoming Q3 2026 earnings report. The stock is currently trading near its 52-week high, reflecting strong recent performance.